Eosinophilia future or investigational therapies

Revision as of 22:39, 29 August 2016 by George Leef (talk | contribs)
Jump to navigation Jump to search

Eosinophilia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eosinophilia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT

MRI

Other imaging findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Eosinophilia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eosinophilia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eosinophilia future or investigational therapies

CDC on Eosinophilia future or investigational therapies

Eosinophilia future or investigational therapies in the news

Blogs on Eosinophilia future or investigational therapies

Directions to Hospitals Treating Eosinophilia

Risk calculators and risk factors for Eosinophilia future or investigational therapies

  • Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases
  • If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts
  • Anti-IL5 antibody Mepolizumab is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids. [1]

References

  1. Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. NEJM 2008; 358:1215-1228